Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
Gastric Cancer, 07/17/2012
Yamaguchi K et al. – Capecitabine plus cisplatin (XP) is effective and well tolerated in Japanese patients with metastatic gastric cancer (mGC), and could be one of the standard regimens for the first–line treatment in this cohort.Methods
- Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies.
- There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2–positive tumors; therefore, efficacy was evaluated separately.
- Ninety–four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone.
- Median overall and progression–free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study.
- Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study.
- Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea.